Kytopen Secures Series B to Tackle Cell Therapy's Biggest Bottleneck

CAMBRIDGE, Mass. and SAN FRANCISCO – April 07, 2026 – Kytopen Corp., a biotechnology firm at the forefront of cellular engineering, has announced the closing of a Series B financing round led by Telegraph Hill Partners. The investment, which includes participation from existing backers, is set to fuel the global commercialization of Kytopen’s innovative Flowfect® technology, a platform designed to solve one of the most significant hurdles in modern medicine: manufacturing cell therapies at scale.

The new capital will accelerate the company's expansion across the United States and Europe, responding to what CEO Michael Chiu calls "strong and growing customer demand." As a key part of the deal, Telegraph Hill Partners, a venture capital firm with a sharp focus on life science infrastructure, will join Kytopen's Board of Directors, signaling strong investor confidence in the company's mission to revolutionize how potentially curative treatments are made.

The High Cost of a Medical Revolution

The field of Advanced Therapy Medicinal Products (ATMPs), which encompasses cell and gene therapies, is one of the fastest-growing sectors in healthcare. Valued at nearly $36 billion in 2024, the market is projected to surge to over $170 billion by 2034, driven by groundbreaking treatments for cancers and rare genetic diseases. Yet, this explosive growth is constrained by a formidable manufacturing bottleneck.

Legacy manufacturing processes are complex, labor-intensive, and exorbitantly expensive, often resulting in therapeutic costs that run into the hundreds of thousands, or even millions, of dollars per patient. These challenges are particularly acute for autologous therapies, which use a patient's own cells. The process of extracting, engineering, and returning these cells is fraught with logistical hurdles, long turnaround times, and a high risk of variability, all of which limit patient access.

Industry experts agree that for cell therapies to become a mainstream standard of care, the underlying manufacturing technology must evolve. The market is in critical need of solutions that can increase efficiency, ensure consistency, and drastically reduce costs without compromising the quality and viability of the final cellular product. This is precisely the challenge Kytopen was founded to address.

Engineering Cells with Speed and Gentleness

Kytopen's core innovation is its Flowfect® platform, a non-viral, continuous-flow system for cell engineering. Traditional methods often rely on viral vectors to deliver genetic payloads into cells—a process that is effective but can be costly, complex to scale, and carries potential safety risks. Other non-viral methods, like conventional electroporation, can be harsh on cells, leading to poor viability and inconsistent results.

The Flowfect® technology offers a distinct alternative. It combines mechanical, electrical, and chemical forces in a controlled, continuous flow, allowing it to gently open cell membranes and deliver genetic material. According to the company, this process can engineer hundreds of billions of high-quality, healthy cells in mere minutes—a scale and speed that dramatically outpaces conventional methods. Its platform includes the Flowfect Discover™ for early-stage research and the Flowfect Tx® for GMP-compliant clinical and commercial manufacturing, providing a seamless path from the lab to the clinic.

This technological advantage has been validated in the market. A comparative study conducted with Charles River Laboratories indicated that the Flowfect Tx™ platform outperformed traditional electroporation systems. The investment from Telegraph Hill Partners further underscores this potential.

"Kytopen's Flowfect technology has demonstrated the ability to genetically modify a broad range of therapeutic cell types in higher quantities, with better cell health and with lower cost than existing methods," said Matthew Mackowski, Chairman and Managing Director at Telegraph Hill Partners. "Adoption of technologies like Kytopen's will be essential to achieving broader community access to potentially curative cell therapies by lowering costs, shortening turn-around-time, and reducing variability."

A Strategic Bet on Industry Infrastructure

The decision by Telegraph Hill Partners (THP) to lead the Series B round is as much a statement about the market as it is about Kytopen itself. THP has a long history of investing in the foundational "picks and shovels" companies that enable entire industries to thrive. Their portfolio is filled with firms that provide critical tools, diagnostics, and manufacturing services, and their investment in Kytopen aligns perfectly with this strategy.

This strategic capital injection, which brings Kytopen's total funding to over $44 million, signals a maturing market for cell therapy infrastructure. Investors are increasingly recognizing that the long-term success of the cell therapy revolution hinges on the companies building the tools to make it scalable and affordable. THP's involvement provides not only capital but also deep industry expertise and a network that can help Kytopen navigate its next phase of growth.

"We welcome Telegraph Hill Partners to our investor base at this pivotal stage," stated Michael Chiu, Kytopen's CEO. "This investment enables us to scale globally while continuing to invest in the infrastructure needed to support our partners in delivering cost-effective, advanced cell therapies worldwide."

Partnerships Paving the Path to Commercial Scale

Kytopen has already laid significant groundwork for its commercial expansion through a series of strategic collaborations across the cell therapy ecosystem. These partnerships are crucial for integrating its Flowfect® technology into real-world manufacturing workflows.

Recent announcements highlight this strategy in action. A collaboration with Aldevron aims to combine Kytopen's platform with Aldevron's Nanoplasmid™ vector technology to create a superior CRISPR-mediated engineering workflow. Another partnership with Bio-Techne integrates the Flowfect® system with Bio-Techne's TcBuster™ non-viral genome engineering system to streamline gene delivery. The company has also joined forces with BlueWhale Bio to develop non-viral manufacturing workflows and expanded its reach into Europe through an agreement with Germany's T-CURX GmbH.

These collaborations demonstrate tangible market adoption and provide a clear pathway for Kytopen's technology to become a new industry standard. By working directly with biotech companies, contract manufacturers (CDMOs), and leading medical centers, the company is ensuring its platform meets the rigorous demands of clinical and commercial production, ultimately accelerating the journey of next-generation therapies from the laboratory to the patients who need them.